Mmf delayed-release tablets are enteric coated formulation of mycophenolate sodium that delivers the Active moiety mycophenolic acid. It is an immunosuppressive agent. It is an uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). Therefore, it inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation to DNA. Ipca Mmf has cytostatic effects on lymphocytes. It has been shown to prevent the occurrence of acute rejection of kidney and heart allotransplantation. It also decreases antibody production.

Before taking Mmf Tablet 10's, inform your doctor if you have a sign of infection such as a fever or sore throat, have any unexpected bruising or bleeding, have a history of digestive system problems such as a stomach ulcer, are planning to become pregnant, get pregnant while taking Mmf Tablet 10's, and have rare hereditary disorders such as Lesch-Nyhan or Kelley-Seegmiller syndrome (conditions caused by a deficiency of the enzyme hypoxanthine-guanine phosphoribosyl-transferase (HGPRT)). Limit your exposure to sunlight as Mmf Tablet 10's increases the risk of skin cancer. Do not donate blood while taking Mmf Tablet 10's and for at least 60 days after discontinuing the therapy. Men should not donate sperm while taking Mmf Tablet 10's for at least 90 days after discontinuing the therapy. Please do not take any vaccinations (live vaccine) as it will not be much effective. The oral suspension contains aspartame (sweetener and a phenylalanine source), so it should be used with caution in patients with phenylketonuria (a birth defect/congenital disability that causes decreased metabolism of phenylalanine).